Stanley Druckenmiller Duquesne Family Office
Stanley Druckenmiller is the founder of Duquesne Family Office and one of the most closely watched macro investors of his generation. He first became widely known as lead portfolio manager of the Quantum Fund alongside George Soros, including during the famous 1992 bet against the British pound. After returning outside capital, he has continued to invest with a flexible, top-down approach that blends macroeconomic views with concentrated equity and commodity positions.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$293M |
| 2 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$223M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$112M |
| 4 |
Sea Limited
SE
|
+$99.2M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$80.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$264M |
| 2 |
Insmed
INSM
|
+$172M |
| 3 |
Natera
NTRA
|
+$147M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$107M |
| 5 |
TSMC
TSM
|
+$65.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.89% |
| 2 | Consumer Discretionary | 15.38% |
| 3 | Technology | 10.8% |
| 4 | Industrials | 9.68% |
| 5 | Communication Services | 5.22% |
Similar funds
Stanley Druckenmiller's Q4 2025 Portfolio in Review
As of Q4 2025, Stanley Druckenmiller held 93 positions worth $4.49B, up 11% from $4.06B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Stanley Druckenmiller's Q4 2025 filing shows 28 new, 13 increased, 16 reduced and 31 closed positions. Its largest new stake was State Street Financial Select Sector SPDR ETF: 5,495,600 shares worth $301M. The largest sale was Teva Pharmaceuticals, an estimated $264M.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 35% a quarter earlier, followed by Consumer Discretionary and Technology.
- Stanley Druckenmiller's largest Q4 2025 buy was State Street Financial Select Sector SPDR ETF: 5,495,600 shares worth $301M.
- Stanley Druckenmiller added most to Sea Limited in Q4 2025, an estimated $99.2M increase.
- Stanley Druckenmiller's biggest Q4 2025 reduction was Teva Pharmaceuticals, cutting an estimated $264M.
- Stanley Druckenmiller fully exited Verona Pharma in Q4 2025, selling an estimated $107M.
- Stanley Druckenmiller's ten largest holdings make up 52% of its $4.49B portfolio in Q4 2025.
- Stanley Druckenmiller opened 28 new positions and closed 31 in Q4 2025.
- Stanley Druckenmiller's portfolio value rose 11% quarter-over-quarter to $4.49B.
Based on Duquesne Family Office's 13F filing for Q4 2025, filed 17 Feb 2026.